fda pulls semaglutide Approves Oral for Weight Loss FDA is moving to restrict

The proportion of non-endocrinologists or diabetes specialists prescribing GLP-1s has grown by over 5 percentage points in the past two years, making up almost 95% of all prescribing physicians

The bridge program is a significant change because Medicare, the federal health program mainly for adults 65 and older, has been prohibited from covering weight loss medications, including GLP-1s

Together, you can develop a plan for transitioning off the medication gradually

The answer is almost always bacteriostatic water, but understanding why helps you make informed decisions in edge cases

For pricing and dosing context on compounded tirzepatide, see our related guide breakdown